|

Darolutamide (Nubeqa, BAY1841788) Clinical Trials

2 actively recruiting trials

No change since May 2026

Also known as: ODM-201

Pipeline

Phase 4: 1

Top Sponsors

  • Bayer2

Indications

  • Non-metastatic Castration-resistant Prostate Cancer2
  • Cancer2
  • Metastatic Hormone-sensitive Prostate Cancer1

Other2 trials

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Phase 4
An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.